Pre-Test Non-CAR T Therapeutic Options for the Treatment and Management of R/R DLBCL Pre-Test 1. Which of the following treatment regimens is suggested in Version 5.2023 of the NCCN Guidelines for second-line therapy in DLBCL patients with no intention to proceed to transplant? Ifosfamide + carboplatin + etoposide +/- rituximab Gemcitabine + dexamethasone + cisplatin +/- rituximab Polatuzumab vedotin-piiq + lenalidomide Tafasitamab-cxix + lenalidomide Unsure 2. In phase 2 of a phase 1-2 study in which patients with R/R DLBCL who had received at least two lines of previous therapy treated with glofitamab, which of the following were the most commonly associated AEs? CRS and peripheral neuropathy CRS and neutropenia Peripheral neuropathy and neutropenia Peripheral neuropathy and pneumonia Unsure 3. Which of the following treatment combinations is limited by pre-existing peripheral neuropathy, especially inpatients previously treated with vinca alkaloids or platinum agents? Polatuzumab + bendamustine + rituximab Polatuzumab + bendamustine + tafasitamab Zilovertamab + bendamustine + rituximab Zilovertamab + bendamustine + tafasitamab Unsure How confident are you in your ability to evaluate current sequencing techniques to develop individualized treatment plans in patients with R/R DLBCL? Very Confident Confident Somewhat confident Not very confident Not at all confident
